ClinicalTrials.gg
CompletedNCT02171052Updated Jun 23, 2014

Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers

A Phase 1 interventional study of Dabigatran etexilate and Digoxin in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-23.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To investigate the bioavailability of dabigatran with and without concomitant administration of digoxin and the bioavailability of digoxin with and without concomitant administration of dabigatran etexilate

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead , clinical laboratory tests

  2. Age ≥18 and ≤65 years
  3. ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
  4. Signed and dated written prior to admission to the study in accordance with GCP and the local legislation.

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Relevant surgery of gastrointestinal tract
  3. History of any bleeding disorder or acute blood coagulation defect
  4. Puls below 50 bpm at screening
  5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  6. History of relevant orthostatic hypotension, fainting spells or blackouts
  7. Chronic or relevant acute infections
  8. History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  9. Intake of any medication within four weeks of first dosing.
  10. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial
  11. Participation in another trial with an drug within two months prior to administration or during the trial
  12. Alcohol abuse (more than 60 g/day)
  13. Drug abuse
  14. Within 5 days of study medication no intake of grapefruit, grapefruit juice, or products containing grapefruit juice, Seville oranges, garlic supplements, or St. John's Worth
  15. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  16. Excessive physical activities (within one week prior to administration or during the trial)
  17. Any laboratory value outside the reference range that is of clinical relevance
  18. Inability to comply with dietary regimen of study centre
  19. Females of child bearing potential who are pregnant, breast feeding or who are either not surgically sterile or are sexually active and not using an acceptable form of as either the oral contraceptives since at least two months and the double barrier method, i.e. intrauterine device with spermicide and condom for the male partner
  20. Male subjects must agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post study medical. Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two month)
  21. Planned surgeries within four weeks following the end-of study examination
  22. Intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, cumarin etc.
  23. The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
  24. Vulnerable subjects (e.g. persons kept in detention).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Dabigatran etexilate plus digoxin

    Drug: Dabigatran etexilate · Drug: Digoxin

  • Active comparator
    Dabigatran etexilate

    Drug: Dabigatran etexilate

  • Active comparator
    Digoxin

    Drug: Digoxin

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)

    Time frame: Up to 72 hours after drug administration on day 4

  2. Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss)

    Time frame: 2 hours before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours after drug administration on day 4

Secondary outcomes

  1. Area under the concentration-time curve of the analyte in plasma from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ (AUC0-tz,ss)

    Time frame: Up to 72 hours after drug administration on day 4

  2. Time of last measurable concentration of the analyte in plasma within the dosing interval τ at steady state (tz,ss)

    Time frame: Up to 72 hours after drug administration on day 4

  3. Time from last dosing to the maximum concentration of the analyte in plasma at steady state (tmax,ss)

    Time frame: Up to 72 hours after drug administration on day 4

  4. Apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration (CL/Fss)

    Time frame: Up to 72 hours after drug administration on day 4

  5. Renal clearance of the analyte at steady state determined over the dosing interval τ (CLR,ss)

    Time frame: Up to 24 hours after drug administration on day 4

  6. Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)

    Time frame: Up to 72 hours after drug administration on day 4

  7. Time from last dosing to the minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ ( tmin,ss)

    Time frame: Up to 72 hours after drug administration on day 4

  8. Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)

    Time frame: 2 hours before drug administration on day 4

  9. Mean residence time of the analyte in the body at steady state after p.o. administration (MRTp.o.,ss)

    Time frame: Up to 72 hours after drug administration on day 4

  10. Fraction of parent drug eliminated in urine at steady state over a uniform dosing interval τ (feτ,ss)

    Time frame: Up to 24 hours after drug administration on day 4

  11. Assessment of tolerability by investigator on a four point scale (good, satisfactory, not satisfactory, bad)

    Time frame: Day 76

  12. Apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration (Vz/Fss)

    Time frame: Up to day 7

  13. Amount of analyte that was eliminated in urine at steady state over an uniform dosing interval τ (Aeτ,ss)

    Time frame: Up to 24 hours after drug administration on day 4

  14. Area under the effect ratio curve (AUERτ,ss) for activated prothrombin time (aPTT) and ecarin clotting time (ECT)

    Time frame: Up to 72 hours after drug administration on day 4

  15. Prolongation at trough (ERpre,ss) for aPTT

    Time frame: Up to 72 hours after drug administration on day 4

  16. Change from baseline in physical examination

    Time frame: Baseline, day 76

  17. Change from baseline in vital signs (blood pressure, pulse rate)

    Time frame: Baseline, day 76

  18. Change from baseline in 12-lead electrocardiogram

    Time frame: Baseline, day 76

  19. Change from baseline in clinical laboratory tests

    Time frame: Baseline, day 76

  20. Number of Participants with Serious and Non-Serious Adverse Events

    Time frame: Up to day 76

  21. Maximum effect ratio at steady state (ERmax,ss) for aPTT and ECT

    Time frame: Up to 72 hours after drug administration on day 4

  22. Prolongation at trough (ERpre,ss) for ECT

    Time frame: Up to 72 hours after drug administration on day 4

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006 and a primary completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 23, 2014
Start
Jun 2006
Primary completionActual
Aug 2006
Last update
Jun 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02171052
Responsible party
Sponsor
First posted
Jun 23, 2014
Start date
Jun 2006
Primary completion
Aug 2006
Last update
Jun 23, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Digoxin

Start the discussion